Despite Heightening Investor Pressure, Few Companies Publicly Report on Sustainability, Sphera’s New Survey Finds

New data from Sphera reveals that, despite promises to the contrary, companies struggle with implementing and disclosing progress on their sustainability efforts

CHICAGO, Sept. 30, 2021 (GLOBE NEWSWIRE) — Though pressure is growing from all corners—from investors, to governments, to boards of directors—companies worldwide struggle to report progress on their Environmental, Social and Governance (ESG) goals. Indeed, just 38% of businesses publicly communicate their sustainability performance, according to a new survey from Sphera®, a leading global provider of ESG performance and risk management software, data and consulting services.

It’s not just a matter of disclosing progress on their objectives, however; companies are also behind the curve when it comes to clearly setting their ESG goals in the first place. Less than one-third (29%) of the respondents said they have set and communicated their sustainability targets, and even fewer—16%—have set emissions targets in accordance with the Science Based Targets initiative (SBTi) framework.

This marked lack of ESG transparency highlights the persistently wide chasm between ESG promises and action in the private sector. In the absence of significant, enforceable regulations worldwide, companies have largely been left to voluntarily make commitments, but with no meaningful mechanisms to either measure their progress or hold themselves accountable to them. About half (51%) of companies surveyed affirm that their senior management has made sustainability commitments, but only 21% say they have a clear roadmap to implementation, and just 26% say they have fully integrated sustainability into their business strategy.

“It’s easy to ‘talk the talk’ when it comes to corporate ESG initiatives, but much harder to ‘walk the walk’,” says Paul Marushka, Sphera’s CEO. “Businesses have largely been left to their own devices to establish and measure their sustainability performance, leading to a constellation of voluntary frameworks that ultimately disincentivize meaningful action. But with the Intergovernmental Panel on Climate Change’s recent report providing its strongest warning yet – indicating that half-measures will no longer cut it – and the upcoming COP26 conference promising to hold the business community to account, organizations need to start making good on their promises and show tangible progress.”

These findings are from Sphera’s Sustainability Survey 2021, a survey of 218 global business leaders evaluating their sustainability metrics, measurement and progress.

Additional findings from the survey include:

Scope 3 is missing from the menu. Though reducing emissions across the value chain is essential to meeting decarbonization targets and—for those businesses who have committed to them—achieving net zero emissions, very few companies have accounted for Scope 3 emissions in their sustainability plans. Only 13% of businesses surveyed said they have identified all relevant Scope 3 categories and completed a corresponding hotspot analysis; 29% say they consider the entire value chain when calculating their corporate emissions baseline or carbon footprint.

“Scope 3 emissions can make up the vast majority of a company’s overall carbon footprint,” Marushka added, “which means any sound sustainability strategy must involve an assessment of the supply chain and a commitment to working with suppliers who are also taking measurable steps to reduce their emissions. The end result ultimately creates a multiplier effect for both companies’ sustainability efforts.”

Poor data quality can stymie even the best efforts. Only a minority of respondents (16%) use data from established commercial databases to quantify their corporate carbon footprint; another 14% say they use high-quality, industry-based data for baseline assessment at the product level. In practice, this means many more organizations are using suboptimal datasets, such as spend-based, input-output databases, to measure their emissions. These types of top-down, nonspecific data sources can lead to inaccurate assessments, further exacerbating the gap between sustainability promises and outcomes.

The middle market struggles the most. Perhaps unsurprisingly, large organizations with more than $1 billion in revenue are more likely to be rated as optimized (34%) in terms of sustainability maturity.1 At the same time, 39% of small businesses with less than $100 million in revenue are considered optimized. Midsize businesses trail both, with an optimization rate of just 30%. In fact, midsize businesses are more likely than their larger or smaller counterparts to not exceed basic compliance requirements (25% vs.13% for smaller organizations and 6% for larger organizations).

About the Sustainability Maturity Survey 2021
Sphera partnered with the University of Esslingen in Germany to design and field a survey of companies throughout Europe, North America and Asia-Pacific. Respondents represented businesses in a wide range of industries, including automotive, construction, education, health care, oil and gas, manufacturing and technology. The survey was conducted between April 7 and May 3.

About Sphera
Sphera creates a safer, more sustainable and productive world. We are a leading global provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services with a focus on Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship.

Press Contact
Kylie Souder
kylie.souder@aspectusgroup.com
+1 513-304-5776

__________________
1
According to Sphera’s Sustainability Maturity rubric, an “optimized” business leverages ESG software and data resources to go above and beyond meeting compliance requirements to help find efficiencies, increase productivity and innovation, reduce costs and mitigate risks. A “leader” is at the head of the competitive pack and is shaping the future of its sector through its sustainability initiatives.

‫13ویں چائنا انٹرنیشنل ایویشن اینڈ ایرو اسپیس ایگزبیشن ژوہائی میں شروع ہوگیا،جوشہر کی آسان رسائی دینے کو ظاہر کرتاہے۔

ژوہائی،چین،30ستمبر،2021 /ژن ہوا-ایشیا نیٹ/ — 28ستمبر کے دن،13ویں چائنا انٹرنیشنل ایویشن اینڈ ایرو اسپیس ایگزبیشن یا ایئر شو چائنا کا جنوبی چین کے صوبہ گوانگڈانگ کے شہر ژوہائی میں باقاعدہ طور پرآغاز ہوگیا۔13ویں چائنا انٹرنیشنل ایویشن اینڈ ایرو اسپیس ایگزبیشن کی انتظامی کمیٹی کے مطابق،روں سال،40کے قریب ممالک اور خطوں سے 700 کمپنیوں نے اس نمائش میں شرکت کی،اور کئی نئی مصنوعات،ٹیکنالوجیاں،سہولیات اور کامیابیاں چین اور دنیا میں پہلی مرتبہ نمائش کے لیے پیش کیے جائیں گی جو دنیا کے جدید معیار نمائندگی کریں گی۔

سول ایویشن کی صنعت،دوہرے استعمال کی ٹیکنالوجی،ایویشن کی تیاری کے مراکز،ایم آر او،خود کار نظام،سمندری دفاعی نظام اور دیگر موضوعاتی نمائشن اس شو میں شامل ہوں گی،جو زمین،سمندر،ہوا،خلا، اور الیکٹرانگ کے شعبوں پر  مشتمل ہوں گی۔

یہ زبردست ہوائی نمائش اور جدید آوزاروں کی شاندار ترتیب چین کی ایرواسپیس صنعت کی خود اعتمادی اور کشادگی کو ظاہر کرتی ہے۔

اس تقریب کا بڑھتا ہوا دائرہ کار اور بین الاقوامی اثر ورسوخ ا کمپنیوں کو ایشیا-پیسفک اور چینی مارکیٹ میں داخلے کا اہم موقع فراہم کرتا ہے۔متظمین کے مطابق، رواں سال نمائش کنندگا ن اور نمائش کا علاقہ اندازے سے بڑھ گئے۔پویلین کی تعداد 8سے بڑھ کر 11ہوئی،جس  میں دنیا بھر کے صنعت کی مشہور کمپنیاں حصہ لے رہی ہیں۔بوئنگ کا نمائش کا علاقہ 11%تک بڑھا اور ائیر بس کا پچھلے سال کی بہ نسبت 65%تک بڑھ گیا۔

سرکردہ کمپنیاں مارکیٹ کے رجحان میں’’بادبہار‘‘سی ہیں،اور معروف ایویشن کمپنیاں ژوہائی آنے کا انتخاب کرتی ہیں،جہاں پر ائیر شو منعقد کیا گیا،جس کے ذریعے کاروبارکو ترقی  دے کر شہر کو ایرو اسپیس صنعت میں ایک ’’نیا ستارہ‘‘بنایاجائے۔

2003سے،جرمنی کی سب سے بڑی انجن بنانے والی کمپنی ایم ٹی یو ایرو انجن اور چائنا سدرن ائیر لائن کمپنی  لمیٹیڈ نے ژوہائی فری ٹریڈ زون میں انجن کی دیکھ بھال  کا ایک مشترکہ منصوبہ بنایا۔اب ،کمپنی نے توسیع کا تیسرا مرحلہ مکمل کیا اور ضلع جنوان میں ایک برانچ پلانٹ بنایا۔

ایم ٹی یو مینٹننس کمپنی لمیٹیڈ کے صدر اور چیف ایگزیکٹیو جاپ بیجر کے مطابق،نئے پلانٹ میں سرمایہ کاری کرنے کا فیصلہ کمپنی کے ایشیائی مارکیٹ اور نیرو-باڈی انجن کی سہولیات کی بڑھتی مانگ کی بہتری اور ترقی کے لیے خوداعتمادی کا تسلسل ہے ۔

ان کا کہناتھا’’ہمیں خوشی ہے کہ ائیر شو میں ہمارے بہت سارے شراکت دار اور صارفین ہیں۔یہ ہمیں کم وقت میں بہت سارے لوگوں کے ساتھ ملنے کا ایک بہت بڑا موقع فراہم کرتاہے۔‘‘

شہرکی مارکیٹ  کے زبردست اندازوں اور پیش نظر کو دیکھتے ہوئے،ایویشن صنعت کے مختلف اقسام،جیسے زراعتی یو اے وی،ایویشن کی نئی اشیائ،انجن کی دیکھ بھال کی سہولیات،ایویشن کی تربیت اور تحقیقی تجربات،اچھی طرح ژوہائی میں ترقی کررہے ہیں۔اعدادوشما رکے مطابق 2020 میں،صرف ضلع جنوان میں ایویشن صنعت کی پیداوار ی ماحصل 58.6%تک بڑھی اور ژوہائی میں ایویشن صنعت بڑھتی جارہی ہے۔

صنعتی ترقی شہری رسائی کی بلند سطح کی جانب اشارہ کرتی ہے۔چین میں پہلے چار خاص معاشی زون میں سے ایک،ژوہائی گزشتہ 40 سال سےاپنی تیز رفتار ترقی کے ذریعے بین الاقوامی تبادلے اور تعاون میں پہلی صف میں کھڑا  رہاہے۔ائیر شو چائنا کے برانڈ کی بڑھتی ہوئی پہچان کی ژوہائی کی آسان رسائی کے  برتاوٗ کے ساتھ ایک مضبوط تعلق ہے۔

اس وقت ،چینی حکومت ہینگ کیون میں گوانگڈانگ-مکاوٗ ان-ڈیپتھ زون کی تعمیر کو فروغ دے رہی ہے،ژوہائی، گہری اصلاحات کے لیے نئی راہوں اور نئے طریقہ کار دریافت کرنے کاقصد رکھتاہے اور گوانگڈانگ-ہانگ کانگ-مکاوٗ گریٹر بے ایریا اور یہاں تک کہ چین کے لیے آسان رسائی دینے کا عزم رکھتاہے۔توقع کی جاتی ہے کہ ژوہائی آسان رسائی کے مواقع ایک نیا سلسلہ شروع کرے گا،اور اس بار یہ صرف ایر واسپیس صنعت کی توجہ حاصل کرنے تک محدود نہیں رہے گا۔ایک  آسان رسائی دینے والا اور موثر شہر،عالمی سرمایہ کاری کےلیے بین الاقوامی معیار کے مطابق ایک اعلی شہر ابھر رہاہے۔

ذریعہ : 13ویں چائنا انٹرنیشنل ایویشن اینڈ ایرو اسپیس ایگزبیشن کی انتظامی کمیٹی

 

QisstPay raises $15M, cementing itself as the fastest growing emerging markets BNPL player from Pakistan

ISLAMABAD, Sept. 29, 2021 /PRNewswire/ — QisstPay, Pakistan’s first and fastest growing buy now pay later platform (BNPL), today announced that they have raised $15M across its seed & pre-seed rounds with a mix of equity and debt. MSA Capital led the round, with institutional investment participation from Global Founders Capital; Fox Ventures, First Check Ventures; and a series of strategic angel investments from Simone Mancini and Johnny Mitrevski, Co-Founders of Scalapay, who recently raised a $155M Series A round at a $700M valuation; Ashley Davies, former CFO of Venmo and current Sylp CFO; former C Suite at Affirm; Adam Mawdesley, VP of Partnerships & Product at Splitit; and United Bank Limited of Pakistan.

QisstPay is an installment payment service for emerging markets offering interest free platform. When chosen at checkout, QisstPay allows customers to pay for their purchase in installments with 0% interest and no late fees. The service allows Pakistanis to pay for everyday necessities, effectively building better cash management in what is otherwise considered a very cash-driven society.

Co-Founder and CEO, Jordan Olivas is a former Klarna employee, who supported the launch of the company’s Pay In 4 solution, one of the world’s biggest BNPL platforms. “After moving here to Pakistan, I noticed how badly the people of this country need a financial tool to help them purchase goods and services that they not only want, but actually need,” says Olivas.

Seeing a week to week growth on 92% rate, QisstPay is currently serving over 500 retailers in Pakistan, including Samsung, Camelbak, Diesel, Philips, Xiaomi MiStore, Lenovo & regional leaders such as Sapphire, Uniworth & the largest Shopify store in the country, elo.

“Export leftovers has recently seen another high of hitting the fastest spike of 85% on average order value ever since we have started to offer QisstPay BNPL to our customers,” says Umar Qamar Co-Founder of Elo, the largest shopify Ecommerce brand in Pakistan.

To learn more, please visit https://qisstpay.com/.

About QisstPay

QisstPay is an installment payment service for emerging markets. QisstPay is a Buy Now, Pay Later platform that, when chosen at checkout, allows customers to pay in installments with 0% interest. They are addressing the lack of flexibility, integration, and the hidden fees currently plaguing Pakistan’s BNPL landscape by giving customers an efficient, adaptable, interest free platform.

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular Injection in Ongoing Phase 2/3 Studies

Data to be Presented During IDWeek 2021 and 19th Annual Discovery on Target Conference

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the company’s COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the company’s ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America’s IDWeek 2021, being held from Sept. 29 – Oct. 3, 2021. In addition, Adagio’s chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19th Annual Discovery on Target Conference on Sept. 30, 2021.

“The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 – which was designed to be potent, broadly neutralizing and delivered as a single IM injection – could have on people with or at risk of COVID-19,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19. We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.”

Phase 1 Trial Update
Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. Importantly, ADG20 was well tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts. Participants will continue to be followed through 12 months to assess safety and tolerability, PK, immunogenicity and serum virus neutralizing activity.

Phase 1 Poster Information: (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Dose Selection Strategy
To support dose selection for Adagio’s global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half-life monoclonal antibodies in serum and key sites of viral replication in the respiratory tract. Adagio’s model adequately a priori predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagio’s Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE.

For the STAMP treatment trial, data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads. Further, for the EVADE prevention trial, data compiled to date suggest the 300 mg IM regimen has a projected ability to rapidly exceed target serum concentrations in the majority of simulated patients and to maintain potentially effective concentrations for up to 12 months.

Dose Selection Poster Information

  • (1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
  • (1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
  • (1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)

The STAMP and EVADE clinical trials are currently ongoing and enrolling patients globally. For more information, please visit clincialtrials.gov.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA application, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Wolters Kluwer Enablon Releases Version 9.3 of Vision Platform Software to Provide 360-Degree Risk Management for Asset-Intensive Enterprises

Companies in asset-intensive industries can achieve increased levels of operational excellence through exclusive holistic view of risk

CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) — Managing risk is now easier for enterprises of all sizes, thanks to Version 9.3 of the Enablon Vision platform. Enablon today announces a brand-new release of its integrated risk management platform, adding enhancements in user navigation, deployment options, mobile use cases and cross-domain functionality: Version 9.3 of the Enablon Vision Platform enables customers to obtain a holistic view of risk across their enterprise, a mandatory requirement to increase operational excellence. Enablon is a Wolters Kluwer business and a global leader in Environmental, Social and Corporate Governance (ESG), Governance, Risk management, and Compliance (GRC), Environment, Health, Safety, and Quality (EHSQ) and Operational Risk Management (ORM) software solutions.

“Organizations now face growing pressure to conduct business in a more responsible, productive, and safe manner,” says Laurent Dechaux, Vice President & Managing Director, Wolters Kluwer Enablon. “Not only is there a shift in expectations from consumers and stakeholders for businesses to do no harm and contribute to a better world, but corporations also face pressure from the market to keep pace with digitization and embrace latest innovations to unlock the full potential of their business.”

Why is 360-Degree Risk Management important?

Data that helps organizations monitor, report, and predict against requirements related to risk is often siloed and stored in disparate systems, and the information needed to make informed decisions is not available to those needing real-time visibility. Version 9.3 of the Enablon Vision platform covers the full range of activities involved with risk, from capturing, measuring, and refining – to managing and predicting risk, in a single platform, with a single user interface and deployment.

“Organizations face challenges in the balance between being a good corporate citizen and being a productive business. To meet those needs, they need a platform that not only allows them to manage risk, but also to make the best decisions possible,” says Rob Davis, Vice President of Product Management, Wolters Kluwer Enablon. “Enablon is the only solution that covers and connects all types of enterprise risk, including operational, environmental, health, safety and quality. Version 9.3 enables our clients to get to the next level and break through the plateau that they are facing in terms of improving safety outcomes, improving operational excellence, efficiency and in making decisions to be more responsible.”

Top 5 Benefits of Enablon Vision Platform Version 9.3:

  1. Single sign-on and enhanced, consistent user interface and navigation: Navigate between capabilities across the platform using one set of credentials for easy access.
  2. Public cloud offering with more options for service continuity: Meet enterprise-class IT requirements through additional worldwide, public cloud deployment options.
  3. Save time in the field with new mobile functionality for Permit to Work and Incident Reporting.
  4. Drive collaboration between previously siloed teams with four cross-domain use cases to manage operational risk:
    • Lessons learned from incidents delivered straight into operational frontline for better Control of Work planning
    • Visualize EHS KPIs within Barrier Management for real-time view on leading indicators
    • Access Bowtie view of risk from the centralized risk register in Risk Management to view level of control effectiveness
    • Access Bowtie view of risk from Barrier Management for full real-time overview of barrier integrity combined with control effectiveness
  5. Address challenges in risk and operations by equipping staff with new expert solutions, including:
    • Calculate aggregated control effectiveness from multiple indicators across the platform
    • Integration with RiskLens to perform financial impact quantification of risks
    • Leverage the Value Reporting Foundation’s SASB framework for ESG reporting through the integration of the SASB Standards and SASB Materiality Map® into the Enablon Vision platform

With Enablon being the only vendor to serve multiple personas in the enterprise using a single integrated risk platform — from boardroom level discussions to supervisors managing controls and barriers onsite — the solution provides a unique capability to integrate key risk data from across the organization into meaningful insights.

Version 9.3 is available now for new Enablon customers and as an upgrade for existing customers. For more information about Enablon’s products and solutions, visit www.enablon.com.

About Enablon, a Wolters Kluwer business
Enablon, a Wolters Kluwer business, is the world’s leading provider of integrated software solutions for risk and compliance; engineering and operations; environment, health, safety and quality (EHSQ) and sustainability. We help create a better world by making organizations responsible, productive and safe through innovative technology. Hundreds of industry-leading enterprises and millions of users worldwide rely on our solutions to minimize risks, increase worker safety, prevent incidents from happening, achieve regulatory compliance and reduce environmental impact. For more information, visit www.enablon.com, and follow us on LinkedIn and Twitter.

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

Media Contact:
Astrid Greve-Spencer
Global Associate Director, Corporate Affairs and Communications
Wolters Kluwer Enablon
M: +1.708.427.8429
E: astrid.greve@wolterskluwer.com

‫2021 ماؤنټین ټورزم او آؤټ ډور اسپورټس باندی د بین الاقوامی کانفرنس افتتاح

د ده سره د شپاړسمی ګوئزہو ټورزم انډسټری ډویلپمنټ کانفرنس آغاز هم وشو۔

ګوئزہو، چین ، 28 ستمبر ، 2021 / پی آر نیوزوائر / – ماؤنټین ټورزم او د آؤټ ډور اسپورټس 2021 باندی بین الاقوامی کانفرنس او شپاړسمی ګوئزہو  ټورزم انډسټری ډویلپمنټ کانفرنس 26 ستمبر ، 2021 له چین د جنوب مغربی صوبے گوئزہو په ښار ټونګرین کښې شروع شو۔ د سږ کال تقریب  محور دا دے چی یو داسی ماډل جوړ کڑی شی کوم سیاحت او د متعلقہ شعبو تر منځه ہم آہنګی پیدا کړی کوم مقصد د صنعت انضمام ژور کولو سره د صوبے سیلانو د پاره سیاحت د تجربے له بہتر جوړول دی۔ قابل غور خبره دا د چی دا واحد کانفرنس دے په کوم کښې تھیم سره نہ یواځی چین بلکہ د غونډی دنیا ماؤنټین ټورزم او د آؤټ ډور اسپورټس امتزاج کړے دے۔

په افتتاحی تقریب کښې د سی پی سی صوبائی کمیټی ډپټی سکریټری او د ګوئزہو عوامی صوبائی حکومت ګورنر لی بنګ جن وینا وکړه ، ” ګوئزہو یو حیرت انګیز لینډ اسکیپ پارک، یو حیرت انګیز کلچر پارک، یو قابل رہائش ہیلتھ پارک، یو ایتھلیټک سپورټس پارک دے۔”https://mma.prnewswire.com/media/1636550/image_1.jpg

نور مخکښې ، د چین مغربی ټرائینګل )صوبہ سیچوان ، صوبہ ګوئیزہو او چونګ کنګ(کښې معیاری فرسټ کلاس د ثقافتی سیاحت صنعت د ترقی د پاره ، 3 واړو خطو د ثقافتی سیاحتی حکامو د تعاون معاہدے باندی دستخط وکړل او په افتتاحی تقریب کښې د ویسټ ټرائینګل کلچرل ټورزم  آپریشن الائنس باقاعدہ قیام اعلان وکړو۔

د تقریب  له بین الاقوامی ذرائع ابلاغ او چیمبرز آف کامرس د نمائندو اړخ نه بھرپور توجہ حاصل شوه۔ د ګوئزہو صوبے انګریزی ژبه پبلسټی ویب سائټ “ایکسپلور بیسټ ان ګوئزہو” د چین نامتو میډیا ګروپونو صحافیان او بلل کوم کښې پیپلز ډیلی ، چائنا میډیا ګروپ او  huanqiu.com  سره سره سمندر نه پوری میډیا تنظیمونو بشمول پی آر نیوزوائر ، پولسکی ریډیو ، یو کے کلچر ټرپ ، انټرنیشنل ډیلی نیوز ، ایل ټیمپو سینا یوروپا ، او لا ووز چین ، نه علاوہ چیمبرز آف کامرس د نمائندو سره نارتھ رائن ویسټ فیلیا ، د جرمنی بین الاقوامی کاروباری ایجنسی او د کونراډ اډینور فاؤنډیشن نمائندو له هم د ګوئزہو دورہ کولو او د سیاحتی حکام اړخ نه غونډی صوبے کښې د صنعت تعمیر او ترقی د پاره اوچت کړی اقداماتو مشاہدہ کولو دعوت درکړو ، د کوم حتمی مقصد صوبے له غونډی دنیا نه راتلونکی مسافرانو د پاره ’’ لازمی دورے’’  په مزل کښې تبدیلول دی۔

تصویر : https://mma.prnewswire.com/media/1636550/image_1.jpg